These indices consist of independent prognostic variables for ICI therapy and higher LDH levels, a decrease in albumin, a higher NLR, and more metastatic sites associated with shorter PFS and OS in patients with NSCLC. The gene discussed is ALB; the disease is non-small cell lung carcinoma.